Throt Uses

• Throt indications
• Throt dosage
• Throt interactions
• Throt side effects
• Throt contraindications

Throt indications

Infectious-inflammatory diseases caused by microorganisms sensitive to erythromycin, including diphtheria, pertussis, trachoma, brucellosis, a disease Legionnaires, sore throat, scarlet fever, otitis media, sinusitis, cholecystitis, pneumonia, gonorrhea, syphilis. Also Throt used for the treatment of infectious-inflammatory diseases caused by pathogens (eg staphylococci) are resistant to penicillin, tetracycline, chloramphenicol, streptomycin.

For external use: acne vulgaris.

For local use: the infectious-inflammatory diseases of eyes.

Throt dosage

Adults: Usual Dose: 250 mg every 6 hrs. This may be increased up to ≥4 g daily according to the severity of the infection.

Children: Age, weight and severity of the infection are important factors in determining the proper dosage. The usual regimen is 30-50 mg/kg/day in divided doses. For more severe infections, this dosage may be doubled.

If administration is desired on a twice-a-day schedule in either adults or children, ½ of the total daily dose may be given every 12 hrs. Twice-a-day dosing is not recommended with doses >1 g daily are administered.

Streptococcal Infections: For the treatment of streptococcal pharyngitis and tonsillitis, the usual dosage range is 20-50 mg/kg/day in divided doses.

In the treatment of group A β-hemolytic streptococcal infections, a therapeutic dosage of erythromycin should be administered for at least 10 days.

In continuous prophylaxis of streptococcal infections in persons with a history of rheumatic heart disease, the dosage is 250 mg twice a day.

For prophylaxis against bacterial endocarditis in penicillin allergic patients with congenital heart disease, rheumatic or other acquired valvular heart disease when undergoing dental procedures or surgical procedures of the upper respiratory tract. The dosage schedule for adults is 1 g (20 mg/kg for children) orally 1 hr before the procedure and then 500 mg (10 mg/kg for children) orally 6 hrs later.

Primary Syphilis: A regimen of Throt 20 g in divided doses over a period of 10 days has been shown to be effective in the treatment of primary syphilis.

Dysenteric Amebiasis: Adults: 250 mg 4 times daily for 10-14 days. Children: 30-50 mg/kg/day in divided doses for 10-14 days.

Pertussis: Although optimum dosage and duration of treatment have not been established, dosage of erythromycin utilized in reported clinical studies was 40-50 mg/kg/day, given in divided doses for 5-14 days.

Legionnaire's Disease: Although optimum doses have not been established, doses utilized in reported clinical data were those recommended (1-4 g Throt daily in divided doses).

Conjunctivitis of the Newborn Caused by C. trachomatis:

Oral erythromycin suspension, 50 mg/kg/day in 4 divided doses for at least 2 weeks.

Pneumonia of Infancy Caused by C. trachomatis: Although the optimum duration of therapy has not been established, the recommended therapy is oral erythromycin suspension, 50 mg/kg/day in 4 divided doses for at least 3 weeks.

Urogenital Infections During Pregnancy Due to C. trachomatis: Although the optimum dose and duration of therapy have not been established, the suggested treatment is erythromycin, 500 mg orally 4 times a day for at least 7 days. For women who cannot tolerate this regimen, a decreased dose of 250 mg orally 4 times a day should be used for at least 14 days.

For adults with uncomplicated urethral, endocervical or rectal infections caused by C. trachomatis in whom tetracyclines are contraindicated or not tolerated, 500 mg orally 4 times a day for at least 7 days.

Throt interactions

With simultaneous use of Throt with theophylline, aminophylline, caffeine, there is an increase in their concentration in blood plasma and thus increases the risk of toxic effects.

Erythromycin increases the concentrations of cyclosporine in the blood plasma and may increase the risk of nephrotoxicity.

Drugs that block tubular secretion prolongs T1/2 of erythromycin.

Incompatible with lincomycin, clindamycin and chloramphenicol (antagonism).

Throt reduces the bactericidal action of beta-lactam antibiotics (penicillins, cephalosporins, carbapenems).

With simultaneous use of erythromycin increases the concentration of theophylline.

At the same time receiving chemotherapy, which is carried metabolism in the liver (carbamazepine, valproic acid, hexobarbital, phenytoin, alfentanil, dizopiramid, lovastatin, bromocriptine), may increase the concentration of these drugs in plasma (an inhibitor of microsomal liver enzymes).

IV injection of erythromycin increases the effects of ethanol (accelerating gastric emptying and decrease the duration of alcohol dehydrogenase in the gastric mucosa).

Erythromycin reduces the clearance of triazolam and midazolam and therefore may increase the pharmacological effects of benzodiazepines.

At the same time taking with terfenadine or astemizole may develop arrhythmias (fibrillation and ventricular flutter, ventricular tachycardia, until death); with dihydroergotamine or non hydrated ergot alkaloids may vasoconstriction to spasm, dysesthesia.

With simultaneous application Throt slows elimination (increases the effect) of methylprednisolone, felodipine and anticoagulants of cumarine series.

In a joint appointment with lovastatin increased rhabdomyolysis.

Erythromycin increases the bioavailability of digoxin.

Erythromycin reduces the effectiveness of hormonal contraceptives.

Throt side effects

The most frequent side effects of erythromycin preparations are gastrointestinal (eg, abdominal cramping and discomfort) and are dose-related. Nausea, vomiting and diarrhea occur frequently with usual oral doses. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.

During prolonged or repeated therapy, there is a possibility of overgrowth of nonsusceptible bacteria or fungi. If such infections arise, the drug should be discontinued and appropriate therapy instituted.

Mild allergic reactions eg, urticaria and other skin rashes have occurred. Serious allergic reactions, including anaphylaxis, have been reported.

There have been isolated reports of hearing loss and/or tinnitus in patients receiving erythromycin. The ototoxic effect of the drug is usually reversible with drug discontinuance. However, in rare instances involving IV administration, the ototoxic effect has been irreversible. Ototoxic effects occur chiefly in patients with renal or hepatic insufficiency and in patients receiving high doses of erythromycin.

Very rarely erythromycin has been associated with QT prolongation and ventricular arrhythmias, including ventricular tachycardia and torsade des pointes.

Several reports of infantile hypertrophic pyloric stenosis have been reported in newborn infants receiving various erythromycin products, including Throt. Erythromycin should be used cautiously in the first 3 months of life.

Throt contraindications

Patients with known hypersensitivity to erythromycin. Patients taking terfenadine, astemizole, cisapride, pimozide, verapamil or diltiazem.

Patients with known history of sensitivity to Throt and for those with preexisting liver disease.

Active ingredient matches for Throt:

Erythromycin Estolate

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology